Hepatocyte-like cell injection for small liver syndrome
Part of Digestive system clinical trials.
This early-phase trial tests an injection of lab-grown liver cells into the stomach muscle to prevent or treat small-for-size syndrome, a condition where a partial liver graft is too small. It may also help people with acute or chronic liver failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver failure or small-for-size syndrome by your doctor.
- You agree to receive an injection of cells into your rectus sheath (the muscle layer covering your abdomen).
- You do not have severe life-threatening diseases in other organs.
- You do not have an uncontrolled active infection or bleeding.
- You are not pregnant or breastfeeding.
- You do not have known severe allergies to CiPS-derived cell products or blood products.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new bioartificial liver made from special cells to support people with severe liver problems, including liver failure or when the liver is too small after surgery. It aims to see if it is safe and can help the liver recover.
This trial tests whether a medication (octreotide) or a minor surgical procedure (tying off a spleen artery) works better to help a smaller-than-ideal liver graft work well after a living donor transplant. The goal is to improve blood flow and prevent complications.
This trial tests whether stem cells from donated umbilical cords can help people with acute-on-chronic liver failure, a sudden worsening of chronic liver disease. The goal is to see if this treatment improves liver function and survival.
This Phase 2 trial tests an injection medicine (F573) to see if it can improve people with liver injury, drug-related liver damage, or liver failure. You may be screened with blood tests, liver stiffness measurements, and possibly symptom checks.
This Phase 1 study tests a new way to place liver cells (in small protective “micro-packages”) inside the belly to treat liver failure. It aims to see whether the treatment is safe and potentially helps liver function in adults with worsening chronic or acute-on-chronic liver failure.
This trial tests if injecting donated liver cells into the main artery feeding the liver can help people with decompensated cirrhosis. It aims to see if this treatment is safe and might improve liver function.
Hear when a new Small-for-Size Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.